The Product — What It Is
Glenmark Pharmaceuticals Inc., USA, has introduced Lacosamide Injection USP in a 200 mg/20 mL (10 mg/mL) concentration, packaged in single-dose vials. This generic formulation serves as a bioequivalent and therapeutically equivalent alternative to the reference listed drug, Vimpat Injection, originally developed by UCB, Inc. under NDA 022254.
The medication is specifically approved for the indications specified on Glenmark’s approved label. By providing a generic version of this established therapy, the company aims to enhance the availability of critical injectable treatments for healthcare providers and patients across the United States medical system.
Commercial Opportunity
- The annual sales for the Vimpat Injection market reached approximately $15.2 million for the 12-month period ending April 2026
- Sales data is sourced from IQVIA National Sales Perspectives, covering both retail and non-retail channels
- Glenmark enters the market as a provider of a therapeutically equivalent generic alternative to the original branded product
- The market includes the brand name drug along with all available therapeutic equivalents currently available in the U.S.
- This launch addresses the demand for affordable, high-quality injectable medications in a specialized therapeutic segment
Strategic Fit
The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.
Business Overview
Glenmark Pharmaceuticals Limited is a global, research-led pharmaceutical organization with a diverse presence in branded, innovative, and generic medicine. The company operates 11 world-class manufacturing facilities across four continents and maintains six cutting-edge R&D centers. Its commercial footprint spans more than 80 countries, with a core focus on therapeutic areas including respiratory, dermatology, and oncology.
Recognized for its manufacturing excellence and innovation, Glenmark was recently positioned among the Top 100 biopharmaceutical companies globally by pharmaceutical sales in 2024, reflecting its significant scale and reach in the global healthcare market.
Financial Context
- Glenmark reported a consolidated operating revenue of ₹16,982.51 crore for the trailing twelve months
- The company's net profit for the most recent quarter showed a significant year-on-year growth of 6,382.02%
- Annual revenue growth for the latest fiscal year stood at 29.83%, outperforming several industry benchmarks
- The firm maintains a strong Trendlyne Durability Score of 80, indicating robust financial health
- Cash flow from operating activities remained positive at ₹3,445.03 crore on an annual basis
